May 13 2026
Fed. Cir. 24-1641 Panel Decision

Actelion Pharmaceuticals Ltd v. Mylan Pharmaceuticals Inc

The United States Court of Appeals for the Federal Circuit affirmed a district court ruling that Mylan Pharmaceuticals did not infringe Actelion Pharmaceuticals' patents for a stable epoprostenol drug formulation. The court held that the patent claim term requiring a pH of thirteen or higher refers to measurements taken at standard temperature, and that Actelion was barred from asserting infringement by equivalence.

May 11 2026
Fed. Cir. 24-2223 Panel Decision

METROM RAIL, LLC v. SIEMENS MOBILITY, INC

The United States Court of Appeals for the Federal Circuit reversed and affirmed in part a Patent Trial and Appeal Board decision regarding railroad collision-avoidance patents. The court held that certain claims were obvious but reversed the finding that other claims were not unpatentable due to a claim construction error.

May 6 2026
Fed. Cir. 25-1110 Panel Decision

Lu v. Hyper Bicycles, Inc.

The United States Court of Appeals for the Federal Circuit affirmed a district court's award of attorney fees to a defendant in a patent infringement case. The appellate court found no abuse of discretion in determining the case was exceptional due to the plaintiff's lack of good faith prosecution.